Résultats de la recherche
10
Tout
Rechercher les filtres
Mot-clé
fda
Genelux Announces Alignment with FDA on Key Elements of the Approval Pathway for Olvi-Vec in Platinum Resistant/Refractory Disease
25 mars 2025 08h30 HE
|
Genelux Corporation
- U.S. Food and Drug Administration states that data from the ongoing OnPrime/GOG-3076 Phase 3 registrational trial could potentially support traditional approval - WESTLAKE VILLAGE, Calif., March ...
Abinopharm, Inc. warmly congratulates partner company EGT Synbio on receiving no objection letter from the FDA for their GRAS notification of Dr.Ergo®Ergothioneine
24 mars 2025 15h35 HE
|
Abinopharm, Inc.
Abinopharm, Inc. and our partner, EGT Synbio, announced our Ergothioneine ingredient received GRAS status from FDA, the 2nd GRAS for Ergothioneine in US.
KRTL Holding Group Announces KRTL Biotech Inc. Signs MOU with Industria Químico Farmacéutica Sigma Corp. S.R.L. to Pursue Strategic International Merger
24 mars 2025 09h00 HE
|
KRTL Holding Group
Lakewood, CO, March 24, 2025 (GLOBE NEWSWIRE) -- KRTL Holding Group Inc. (OTC: KRTL), a diversified holding company operating through its subsidiaries KRTL Biotech, Inc. and KRTL International...
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
24 mars 2025 07h00 HE
|
Lexeo Therapeutics
Lexeo Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Operational Highlights
Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones
21 mars 2025 09h28 HE
|
Clearmind Medicine Inc.
Vancouver, Canada, March 21, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and...
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease
20 mars 2025 09h00 HE
|
Longeveron
Longeveron reaches alignment with US FDA on single, pivotal clinical trial to BLA submission for cell therapy for treatment of Alzheimer's disease.
PEP-Therapy receives FDA Orphan Drug Designation for PEP-010 for treatment of Pancreatic Cancer
17 mars 2025 09h00 HE
|
PEP-Therapy
Press release PEP-Therapy receives FDA Orphan Drug Designation for PEP-010for treatment of Pancreatic Cancer Paris (France), March 17, 2025 – PEP-Therapy, a clinical-stage biotechnology company...
ExoPTEN Preclinical Study Demonstrates Significant Potential for Enhancing Motor Function, Blood Flow, and Spinal Cord Injury Recovery
14 mars 2025 16h03 HE
|
NurExone Biologic Inc
ExoPTEN’s Preclinical Study Demonstrates Significant for Enhancing Motor Function, Increasing Blood Flow, and Faster Recovery After Spinal Cord Injuries
Hepion Pharmaceuticals Announces Reverse Stock Split
14 mars 2025 08h30 HE
|
Hepion Pharmaceuticals, Inc.
Shares Expected to Begin Trading on Split-Adjusted Basis on March 18, 2025 MORRISTOWN, N.J., March 14, 2025 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ: HEPA), a clinical stage...
Spineart and eCential Robotics announce FDA clearance of PERLA® App for use with Op.nTM robotic navigation platform
13 mars 2025 05h56 HE
|
Spineart
FOR IMMEDIATE RELEASE Spineart and eCential Robotics announce FDA clearance of PERLA® App for use with Op.nTM robotic navigation platform Dallas, Texas and Franklin, Tennessee, March 13, 2025 —...